Diabetic Neuropathy Recommendations

	2016 ADA Guideline Recommendations
Types of Diabetes Mellitus
Main Diabetes Page
Diabetes type I
Diabetes type II
Gestational Diabetes Mellitus
2016 ADA Standard of Medical Care Guideline Recommendations
Strategies for Improving Care
Classification and Diagnosis of Diabetes
Foundations of Care and Comprehensive Medical Evaluation Diabetes Self-Management, Education, and Support Nutritional Therapy
Prevention or Delay of Type II Diabetes
Glycemic Targets
Obesity Management for Treatment of Type II Diabetes
Approaches to Glycemic Treatment
Cardiovascular Disease and Risk Management Hypertension and Blood Pressure Control Lipid Management Antiplatelet Agents Coronary Heart Disease
Microvascular Complications and Foot Care Diabetic Kidney Disease Diabetic Retinopathy Diabetic Neuropathy Diabetic Footcare
Older Adults with Diabetes
Children and Adolescents with Diabetes Management of Cardiovascular Risk Factors in Children and Adolescents with Diabetes Microvascular Complications in Children and Adolescents with Diabetes
Management of Diabetes in Pregnancy
Diabetes Care in the Hospital Setting

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]; Tarek Nafee, M.D. [3]

2016 ADA Standards of Medical Care in Diabetes Guidelines^[1][edit | edit source]

"1. All patients should be assessed for diabetic peripheral neuropathy starting at diagnosis of type 2 di- abetes and 5 years after the diag- nosis of type 1 diabetes and at least annually thereafter. (Level of Evidence: B)"
"2. Assessment should include a careful history and 10-g monofilament testing and at least one of the following tests: pinprick, temperature, or vibration sensation. (Level of Evidence: B)"
"3.Symptoms and signs of autonomic neuropathy should be assessed in patients with microvascular and neuropathic complications. (Level of Evidence: E)"

"1. Optimize glucose control to pre- vent or delay the development of neuropathy in patients with type 1 diabetes A and to slow the pro- gression of neuropathy in patients with type 2 diabetes. (Level of Evidence: B)"
"2. Assess and treat patients to reduce pain related to diabetic peripheral neuropathy B and symptoms of au- tonomic neuropathy and to im- prove quality of life. (Level of Evidence: E)"